| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Tumor Suppressor Protein p53 | 9 | 2023 | 83 | 3.470 |
Why?
|
| Drug Resistance, Neoplasm | 8 | 2024 | 53 | 3.360 |
Why?
|
| Proto-Oncogene Proteins c-akt | 8 | 2022 | 49 | 2.650 |
Why?
|
| Imidazoles | 7 | 2019 | 50 | 2.570 |
Why?
|
| Piperazines | 7 | 2019 | 75 | 2.530 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 4 | 2023 | 240 | 2.530 |
Why?
|
| Receptors, Estrogen | 4 | 2022 | 54 | 2.330 |
Why?
|
| Autophagy | 7 | 2021 | 30 | 2.210 |
Why?
|
| Antineoplastic Agents | 7 | 2024 | 150 | 2.200 |
Why?
|
| Tamoxifen | 4 | 2022 | 28 | 1.740 |
Why?
|
| Cell Line, Tumor | 16 | 2024 | 234 | 1.730 |
Why?
|
| Breast Neoplasms | 6 | 2022 | 379 | 1.730 |
Why?
|
| Lung Neoplasms | 4 | 2023 | 544 | 1.710 |
Why?
|
| Cisplatin | 5 | 2022 | 50 | 1.420 |
Why?
|
| Apoptosis | 8 | 2019 | 193 | 1.170 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2024 | 16 | 1.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2024 | 106 | 1.060 |
Why?
|
| Carboxypeptidases | 3 | 2022 | 6 | 1.020 |
Why?
|
| Neoplasms | 2 | 2018 | 215 | 1.010 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 3 | 2022 | 6 | 1.000 |
Why?
|
| Myeloid Cell Leukemia Sequence 1 Protein | 1 | 2024 | 4 | 0.900 |
Why?
|
| Glycolysis | 3 | 2018 | 10 | 0.800 |
Why?
|
| Retinoblastoma-Like Protein p130 | 1 | 2022 | 2 | 0.770 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2022 | 172 | 0.750 |
Why?
|
| Fatty Acids | 1 | 2021 | 38 | 0.740 |
Why?
|
| Signal Transduction | 6 | 2021 | 401 | 0.710 |
Why?
|
| Proto-Oncogene Proteins c-vav | 3 | 2010 | 5 | 0.700 |
Why?
|
| Humans | 29 | 2024 | 25165 | 0.640 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2021 | 38 | 0.630 |
Why?
|
| Insulin Receptor Substrate Proteins | 2 | 2020 | 13 | 0.630 |
Why?
|
| Ketoglutarate Dehydrogenase Complex | 1 | 2018 | 2 | 0.620 |
Why?
|
| Ketoglutaric Acids | 1 | 2018 | 2 | 0.620 |
Why?
|
| Sp1 Transcription Factor | 1 | 2018 | 4 | 0.610 |
Why?
|
| Proto-Oncogene Proteins c-cbl | 5 | 2010 | 12 | 0.600 |
Why?
|
| Ubiquitin-Protein Ligases | 4 | 2007 | 23 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 4 | 2019 | 29 | 0.560 |
Why?
|
| ErbB Receptors | 2 | 2010 | 50 | 0.560 |
Why?
|
| Cell Lineage | 1 | 2015 | 22 | 0.500 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2017 | 39 | 0.470 |
Why?
|
| Extracellular Signal-Regulated MAP Kinases | 1 | 2014 | 28 | 0.460 |
Why?
|
| Serine Endopeptidases | 1 | 2014 | 14 | 0.460 |
Why?
|
| Sirolimus | 1 | 2014 | 16 | 0.450 |
Why?
|
| Nitric Oxide | 1 | 2014 | 77 | 0.450 |
Why?
|
| Protein Kinases | 1 | 2014 | 12 | 0.440 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2004 | 33 | 0.440 |
Why?
|
| MCF-7 Cells | 3 | 2021 | 13 | 0.430 |
Why?
|
| cdc42 GTP-Binding Protein | 2 | 2010 | 6 | 0.420 |
Why?
|
| Mice | 10 | 2022 | 1300 | 0.420 |
Why?
|
| rac1 GTP-Binding Protein | 2 | 2010 | 12 | 0.420 |
Why?
|
| rhoA GTP-Binding Protein | 2 | 2009 | 6 | 0.410 |
Why?
|
| Mammary Glands, Human | 2 | 2009 | 7 | 0.410 |
Why?
|
| Paclitaxel | 2 | 2022 | 46 | 0.400 |
Why?
|
| RNA, Small Interfering | 3 | 2019 | 72 | 0.390 |
Why?
|
| Enzyme Activation | 5 | 2014 | 113 | 0.390 |
Why?
|
| Animals | 12 | 2022 | 3430 | 0.370 |
Why?
|
| Cytotoxins | 1 | 2010 | 1 | 0.360 |
Why?
|
| Adherens Junctions | 1 | 2010 | 3 | 0.360 |
Why?
|
| Neoplasm Proteins | 1 | 2010 | 52 | 0.350 |
Why?
|
| Epithelial Cells | 1 | 2010 | 71 | 0.340 |
Why?
|
| Cell Movement | 1 | 2010 | 76 | 0.340 |
Why?
|
| Cell Proliferation | 1 | 2010 | 164 | 0.340 |
Why?
|
| Morphogenesis | 1 | 2009 | 6 | 0.330 |
Why?
|
| Osteosarcoma | 3 | 2018 | 31 | 0.320 |
Why?
|
| Methylation | 2 | 2019 | 9 | 0.320 |
Why?
|
| Histones | 2 | 2019 | 27 | 0.320 |
Why?
|
| Ubiquitin | 5 | 2007 | 29 | 0.310 |
Why?
|
| Cell Cycle Checkpoints | 2 | 2022 | 5 | 0.310 |
Why?
|
| Bone Neoplasms | 3 | 2018 | 112 | 0.300 |
Why?
|
| Mechanistic Target of Rapamycin Complex 1 | 2 | 2018 | 10 | 0.280 |
Why?
|
| Cell Survival | 2 | 2019 | 111 | 0.280 |
Why?
|
| Antineoplastic Agents, Hormonal | 2 | 2021 | 17 | 0.280 |
Why?
|
| Checkpoint Kinase 1 | 2 | 2019 | 5 | 0.270 |
Why?
|
| Phosphorylation | 6 | 2016 | 136 | 0.270 |
Why?
|
| RNA Interference | 2 | 2019 | 35 | 0.270 |
Why?
|
| Retroviridae Proteins, Oncogenic | 2 | 2003 | 2 | 0.270 |
Why?
|
| Gene Knockdown Techniques | 2 | 2018 | 39 | 0.260 |
Why?
|
| Female | 7 | 2024 | 14161 | 0.250 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 2 | 2016 | 8 | 0.240 |
Why?
|
| Oxygen | 2 | 2015 | 64 | 0.230 |
Why?
|
| Receptors, Antigen | 1 | 2004 | 1 | 0.230 |
Why?
|
| Proto-Oncogene Protein c-ets-1 | 1 | 2024 | 2 | 0.230 |
Why?
|
| Interleukin-6 | 1 | 2024 | 73 | 0.220 |
Why?
|
| Histone Deacetylase 1 | 1 | 2023 | 3 | 0.220 |
Why?
|
| Retinoblastoma Protein | 1 | 2023 | 10 | 0.220 |
Why?
|
| Benzamides | 1 | 2023 | 13 | 0.220 |
Why?
|
| Lysosomes | 1 | 2003 | 25 | 0.210 |
Why?
|
| Histone Demethylases | 1 | 2022 | 2 | 0.210 |
Why?
|
| Lysine | 1 | 2022 | 13 | 0.210 |
Why?
|
| Cadherins | 1 | 2022 | 32 | 0.210 |
Why?
|
| Estrogen Receptor alpha | 1 | 2022 | 15 | 0.210 |
Why?
|
| Antigens, CD | 1 | 2022 | 46 | 0.200 |
Why?
|
| CD27 Ligand | 1 | 2022 | 2 | 0.200 |
Why?
|
| MAP Kinase Kinase Kinases | 1 | 2022 | 3 | 0.200 |
Why?
|
| Biomarkers, Tumor | 1 | 2024 | 184 | 0.200 |
Why?
|
| Nanoparticles | 1 | 2022 | 10 | 0.200 |
Why?
|
| Trastuzumab | 1 | 2022 | 24 | 0.200 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2022 | 13 | 0.200 |
Why?
|
| Aurora Kinase B | 1 | 2022 | 2 | 0.190 |
Why?
|
| Aurora Kinase A | 1 | 2022 | 3 | 0.190 |
Why?
|
| Oxidation-Reduction | 1 | 2021 | 60 | 0.190 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2017 | 17 | 0.170 |
Why?
|
| Cell Line | 4 | 2010 | 251 | 0.160 |
Why?
|
| Autophagy-Related Proteins | 1 | 2019 | 3 | 0.160 |
Why?
|
| Ataxia Telangiectasia Mutated Proteins | 1 | 2019 | 3 | 0.160 |
Why?
|
| A549 Cells | 1 | 2018 | 10 | 0.150 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2018 | 2 | 0.150 |
Why?
|
| Mutation | 4 | 2010 | 320 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2018 | 19 | 0.150 |
Why?
|
| Adenosine | 1 | 2018 | 7 | 0.150 |
Why?
|
| Heterocyclic Compounds, 3-Ring | 2 | 2017 | 12 | 0.150 |
Why?
|
| Receptors, Somatomedin | 1 | 2017 | 4 | 0.140 |
Why?
|
| Phospholipase C gamma | 2 | 2007 | 8 | 0.140 |
Why?
|
| Epidermal Growth Factor | 2 | 2010 | 27 | 0.140 |
Why?
|
| Loss of Heterozygosity | 1 | 2016 | 5 | 0.130 |
Why?
|
| DNA Mismatch Repair | 1 | 2016 | 7 | 0.130 |
Why?
|
| Biological Assay | 1 | 2016 | 8 | 0.130 |
Why?
|
| Macrolides | 1 | 2015 | 5 | 0.130 |
Why?
|
| Caspase 8 | 1 | 2015 | 9 | 0.130 |
Why?
|
| Superoxides | 1 | 2015 | 24 | 0.120 |
Why?
|
| Chloroquine | 1 | 2015 | 6 | 0.120 |
Why?
|
| Microscopy, Electron, Transmission | 1 | 2015 | 23 | 0.120 |
Why?
|
| Cellular Senescence | 1 | 2015 | 16 | 0.120 |
Why?
|
| Microscopy, Electron | 1 | 2015 | 62 | 0.120 |
Why?
|
| Microscopy, Confocal | 1 | 2015 | 82 | 0.120 |
Why?
|
| Flow Cytometry | 1 | 2015 | 99 | 0.120 |
Why?
|
| Phagosomes | 1 | 2014 | 3 | 0.120 |
Why?
|
| DNA Methylation | 1 | 2016 | 151 | 0.120 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2014 | 19 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 1 | 2014 | 9 | 0.120 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2014 | 38 | 0.110 |
Why?
|
| DNA Primers | 1 | 2014 | 48 | 0.110 |
Why?
|
| Colorectal Neoplasms | 1 | 2016 | 107 | 0.110 |
Why?
|
| MAP Kinase Signaling System | 1 | 2014 | 34 | 0.110 |
Why?
|
| Base Sequence | 1 | 2014 | 104 | 0.110 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2014 | 66 | 0.110 |
Why?
|
| Models, Biological | 1 | 2016 | 313 | 0.110 |
Why?
|
| DNA Damage | 1 | 2014 | 23 | 0.110 |
Why?
|
| Gene Expression Regulation | 2 | 2007 | 252 | 0.110 |
Why?
|
| Transfection | 3 | 2020 | 113 | 0.110 |
Why?
|
| Estrogen Antagonists | 1 | 2010 | 3 | 0.090 |
Why?
|
| Cell Adhesion | 1 | 2010 | 30 | 0.090 |
Why?
|
| Ubiquitination | 1 | 2010 | 14 | 0.090 |
Why?
|
| Protein Transport | 1 | 2010 | 31 | 0.090 |
Why?
|
| Actins | 1 | 2010 | 34 | 0.090 |
Why?
|
| Cytoskeleton | 1 | 2010 | 34 | 0.090 |
Why?
|
| Amino Acid Sequence | 1 | 2010 | 147 | 0.090 |
Why?
|
| Molecular Sequence Data | 1 | 2010 | 186 | 0.090 |
Why?
|
| Cell Line, Transformed | 1 | 2009 | 15 | 0.080 |
Why?
|
| Precancerous Conditions | 1 | 2009 | 25 | 0.080 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2009 | 29 | 0.080 |
Why?
|
| src-Family Kinases | 2 | 2004 | 6 | 0.070 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2007 | 4 | 0.070 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 1 | 2007 | 9 | 0.070 |
Why?
|
| Neovascularization, Physiologic | 1 | 2007 | 19 | 0.070 |
Why?
|
| Oncogene Protein v-cbl | 2 | 2003 | 2 | 0.070 |
Why?
|
| Mice, Nude | 2 | 2020 | 22 | 0.060 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2004 | 11 | 0.060 |
Why?
|
| Immune Tolerance | 1 | 2004 | 13 | 0.060 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2004 | 14 | 0.060 |
Why?
|
| Oncogene Proteins | 1 | 2003 | 6 | 0.050 |
Why?
|
| CHO Cells | 1 | 2003 | 10 | 0.050 |
Why?
|
| Mice, Knockout | 1 | 2004 | 278 | 0.050 |
Why?
|
| Embryo, Mammalian | 1 | 2003 | 20 | 0.050 |
Why?
|
| Cricetinae | 1 | 2003 | 34 | 0.050 |
Why?
|
| Endosomes | 1 | 2003 | 8 | 0.050 |
Why?
|
| Endocytosis | 1 | 2003 | 17 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 60 | 0.050 |
Why?
|
| Fibroblasts | 1 | 2003 | 52 | 0.050 |
Why?
|
| Blotting, Western | 1 | 2003 | 141 | 0.050 |
Why?
|
| Down-Regulation | 1 | 2003 | 97 | 0.050 |
Why?
|
| Caspase 9 | 1 | 2022 | 8 | 0.050 |
Why?
|
| Caspase 3 | 1 | 2022 | 20 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2022 | 22 | 0.050 |
Why?
|
| Ceramides | 1 | 2022 | 14 | 0.050 |
Why?
|
| Gene Expression | 1 | 2003 | 186 | 0.050 |
Why?
|
| Receptor, ErbB-2 | 1 | 2022 | 44 | 0.050 |
Why?
|
| RNA, Messenger | 1 | 2003 | 293 | 0.050 |
Why?
|
| Protein Binding | 3 | 2007 | 119 | 0.040 |
Why?
|
| Disease Models, Animal | 1 | 2020 | 567 | 0.040 |
Why?
|
| Pyrazines | 1 | 2017 | 8 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 36 | 0.040 |
Why?
|
| Receptor Cross-Talk | 1 | 2016 | 6 | 0.030 |
Why?
|
| Tyrosine | 2 | 2007 | 23 | 0.030 |
Why?
|
| Protein Structure, Tertiary | 2 | 2007 | 58 | 0.030 |
Why?
|
| Computer Simulation | 1 | 2016 | 186 | 0.030 |
Why?
|
| rho-Associated Kinases | 1 | 2009 | 4 | 0.020 |
Why?
|
| Telomerase | 1 | 2009 | 9 | 0.020 |
Why?
|
| Protein Kinase C | 1 | 2009 | 47 | 0.020 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2009 | 58 | 0.020 |
Why?
|
| Ligands | 1 | 2007 | 35 | 0.020 |
Why?
|
| Binding Sites | 1 | 2007 | 71 | 0.020 |
Why?
|
| Mutagenesis, Site-Directed | 1 | 2007 | 17 | 0.020 |
Why?
|
| Gene Silencing | 1 | 2007 | 21 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2007 | 110 | 0.020 |
Why?
|
| Wound Healing | 1 | 2007 | 142 | 0.020 |
Why?
|
| Molecular Conformation | 1 | 2004 | 9 | 0.010 |
Why?
|
| Structure-Activity Relationship | 1 | 2004 | 33 | 0.010 |
Why?
|
| Male | 1 | 2020 | 13815 | 0.010 |
Why?
|
| Vanadates | 1 | 2003 | 3 | 0.010 |
Why?
|
| Jurkat Cells | 1 | 2003 | 9 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2003 | 11 | 0.010 |
Why?
|
| Luciferases | 1 | 2003 | 22 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2003 | 27 | 0.010 |
Why?
|
| Immunoblotting | 1 | 2003 | 54 | 0.010 |
Why?
|
| Plasmids | 1 | 2003 | 45 | 0.010 |
Why?
|
| Models, Genetic | 1 | 2003 | 39 | 0.010 |
Why?
|
| Mice, Transgenic | 1 | 2003 | 209 | 0.010 |
Why?
|
| Time Factors | 1 | 2003 | 1336 | 0.010 |
Why?
|